📰 Director Sciences News
Director Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Director Sciences. Real-time updates on events, politics, business and more.
December 25, 2023
Immunovant (NASDAQ:IMVT – Free Report) had its target price raised by HC Wainwright from $47.00 to $51.00 in a research report released on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. A number of other equities analysts also recently weighed in on the company. Deutsche Bank Aktiengesellschaft assumed coverage on […]
December 20, 2023
Edge Wealth Management LLC reduced its stake in Roivant Sciences Ltd. (NASDAQ:ROIV – Free Report) by 23.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 134,528 shares of the company’s stock after selling 41,004 shares during the period. Edge Wealth Management LLC’s holdings […]
December 15, 2023
Deutsche Bank Aktiengesellschaft initiated coverage on shares of Immunovant (NASDAQ:IMVT – Free Report) in a research note released on Tuesday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $50.00 price objective on the stock. A number of other research analysts have also recently commented on the stock. UBS Group upped their price […]
October 28, 2023
Immunovant (NASDAQ:IMVT – Free Report) had its target price hoisted by HC Wainwright from $29.00 to $47.00 in a report published on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, FY2024 […]
October 27, 2023
Immunovant (NASDAQ:IMVT – Free Report) had its price target boosted by HC Wainwright from $29.00 to $47.00 in a research report released on Tuesday, Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Immunovant’s Q3 2024 earnings at ($0.55) EPS, Q4 2024 earnings at ($0.55) EPS, […]
October 20, 2023
Immunovant (NASDAQ:IMVT – Free Report) had its price target hoisted by Cantor Fitzgerald from $30.00 to $45.00 in a report issued on Monday, Benzinga reports. They currently have an overweight rating on the stock. A number of other research analysts have also commented on the stock. UBS Group upgraded shares of Immunovant from a neutral […]